Skip to main content

ADVERTISEMENT

Mood Disorders

In the SKYLARK Study, zuranolone 50 mg was generally well tolerated in adults with postpartum depression; treatment-emergent adverse events (TEAEs) led to zuranolone dose reduction and di...
10/26/2023
This study examined the utilization pattern of augmentation with atypical antipsychotics after partial or no response to antidepressants in patients with MDD. The antidepressant prescript...
10/26/2023
The Rapid Mood Screener (RMS) is a self-administered screening tool to help differentiate bipolar I disorder from major depressive disorder. Cases were identified from a primary care sett...
10/26/2023
Researchers conducted qualitative interviews to understand patients’ experiences with and perceptions of zuranolone, an oral, investigational, once-daily, 14-day treatment course in clini...
10/26/2023
This safety analysis evaluated the duration of treatment-emergent adverse events (TEAEs) reported for esketamine nasal spray (ESK-NS) versus quetiapine extended release (QTP-XR) in patien...
10/26/2023
This large, cross-sectional, observational study will be conducted in a sample reflecting bipolar I disorder prevalence in real-world settings to confirm the performance of the Rapid Mood...
10/26/2023
Zuranolone 50 mg initiated alone (WATERFALL Study) or co-initiated with a standard-of-care antidepressant (CORAL Study) was well-tolerated in adults with major depressive disorder. In WAT...
10/26/2023
The Pathway Platform supports MBC for patients with MDD by integrating a patient-facing app with EHR. This real-world Pathway Platform implementation study in primary care demonstrated si...
10/26/2023
This research examined real-world safety data for esketamine nasal spray (ESK) for the first 46 months after product approval, with a focus on adverse events (AEs) of interest (i.e., seda...
10/26/2023
This qualitative research study assessed the patient experience of anhedonia and its impacts among patients with MDD. Semi-structured concept elicitation interviews were conducted with 1...
10/26/2023